Toggle navigation
Our Science
1. Discovery
2. The Target: TRPV6
3. Mechanism of Action
4. Intellectual Property
Oncology Programs
SOR-C13
Peptide-Drug Conjugate
About
Our Team
For Investors
News and Events
Resources
Contact
CLOSE
Toggle navigation
Our Science
1. Discovery
2. The Target: TRPV6
3. Mechanism of Action
4. Intellectual Property
Oncology Programs
SOR-C13
Peptide-Drug Conjugate
About
Our Team
For Investors
News and Events
Resources
Contact
October 2, 2019
Professor Jack Stewart, Chief Scientific Officer, explains the mechanism of action of Soricimed's lead drug candidate, SOR-C13.
iFrame is not supported!
Sign up to receive updates from Soricimed
Submit
Powered by Innovasium